Page last updated: 2024-12-06

leucomalachite green

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Leucomalachite green (LMG) is a colorless, non-fluorescent compound that is a precursor to the triphenylmethane dye, malachite green. It is synthesized by reacting benzaldehyde with dimethylaniline in the presence of a strong acid. LMG is an important intermediate in the production of malachite green, which is used as a dye, an antifungal agent, and a biological stain. LMG itself has been studied for its potential use as a fluorescent probe for biological applications. However, it is important to note that malachite green and its precursors have been shown to be toxic to aquatic organisms and have been banned for use in aquaculture in many countries.'

Cross-References

ID SourceID
PubMed CID67215
CHEMBL ID1898627
CHEBI ID181416
SCHEMBL ID61350
MeSH IDM0064491

Synonyms (76)

Synonym
4-[[4-(dimethylamino)phenyl]-phenylmethyl]-n,n-dimethylaniline
CHEBI:181416
129-73-7
nsc36379
bis[4,4'-(dimethylamino)phenyl]phenyl methane
leucomalachite green ,
p,n-dimethylaniline)
nsc-36379
4,4'-bis(dimethylamino)triphenylmethane
c.i. basic green 4, leuco base
bis(p-dimethylaminophenyl)phenylmethane
benzenamine,4'-(phenylmethylene)bis[n,n-dimethyl-
aniline,4'-benzylidenebis[n,n-dimethyl-
4,n-dimethylaminophenyl)phenylmethane
malachite green leuco
tetramethyldiaminotriphenylmethane
malachite green leuco base
bis[p-(n,n-dimethylamino)phenyl]phenylmethane
leuco malachite green
p,p'-benzylidenebis(n,n-dimethylaniline)
bis(p-(n,n-dimethylamino)phenyl)phenylmethane
einecs 204-961-9
4,4'-bis(n,n-dimethylaminophenyl)phenylmethane
bis(4,4'-(dimethylamino)phenyl)phenyl methane
ai3-22125
n,n,n',n'-tetramethyl-4,4'-benzylidenedianiline
4,4'-(phenylmethylene)bis(n,n-dimethylbenzenamine)
4,4'-benzylidene bis(n,n-dimethylaniline)
brn 2140506
aniline, 4,4'-benzylidenebis(n,n-dimethyl-
nsc 36379
benzenamine, 4,4'-(phenylmethylene)bis(n,n-dimethyl-
NCGC00164047-01
4,4'-(phenylmethylene)bis(n,n-dimethylaniline)
4,4'-benzylidenebis(n,n-dimethylaniline)
B0419
4,4'-tetramethyldiaminotriphenylmethane
3BTL
3BTC
unii-8u61g37z20
8u61g37z20 ,
4-13-00-00481 (beilstein handbook reference)
hsdb 8047
ccris 8665
dtxsid7031531 ,
cas-129-73-7
tox21_302103
NCGC00255258-01
dtxcid5011531
benzenamine,4,4'-(phenylmethylene)bis[n,n-dimethyl-
FT-0670767
FT-0631756
AKOS015903777
leucomalachite green [mi]
S6269
SCHEMBL61350
benzenamine, 4,4'-(phenylmethylene)bis[n,n-dimethyl-
beta-cyclopentyl-dl-alanine
CHEMBL1898627
n-(4-[[4-(dimethylamino)phenyl](phenyl)methyl]phenyl)-n,n-dimethylamine #
p,p'-benzylidene bis(n,n-dimethylaniline)
W-109477
mfcd00008315
leucomalachite green, analytical standard
leucomalachite green, certified reference material, tracecert(r)
CS-0010212
HY-D0300
leucomalachite green 10 microg/ml in cyclohexane
leucomalachitegreen
malachitgra(1/4)n
AS-10441
aniline, 4,4'-benzylidenebis(n,n-dimethyl- (8ci)
Q27271024
D88641
leucomalachite green 4,4'-benzylidenebis(n,n-dimethylaniline))
leucomalachite green-methyl-13c4, 98%, 98 atom%13c

Research Excerpts

Overview

Leucomalachite green is a persistent and prevalent metabolite of malachite green. It has been used widely as an antifungal agent in the fish industry.

ExcerptReferenceRelevance
"Leucomalachite green is a persistent and prevalent metabolite of malachite green, a triphenylmethane dye that has been used widely as an antifungal agent in the fish industry. "( Mutagenicity and carcinogenicity in relation to DNA adduct formation in rats fed leucomalachite green.
Beland, FA; Benson, RW; Blankenship, LR; Culp, SJ; Greenlees, KJ; Heflich, RH; Manjanatha, MG; Mellick, PW; Shelton, SD; Trotter, RW; Webb, PJ, 2002
)
1.98

Actions

ExcerptReferenceRelevance
"Leucomalachite green caused an increase in cancer of the liver in female mice."( Toxicology and carcinogenesis studies of malachite green chloride and leucomalachite green. (CAS NOS. 569-64-2 and 129-73-7) in F344/N rats and B6C3F1 mice (feed studies).
, 2005
)
1.28

Toxicity

ExcerptReferenceRelevance
" A comparison of adverse effects suggests that exposure of rats or mice to leucomalachite green causes a greater number of and more severe changes than exposure to malachite green."( Toxicity and metabolism of malachite green and leucomalachite green during short-term feeding to Fischer 344 rats and B6C3F1 mice.
Beland, FA; Blankenship, LR; Culp, SJ; Doerge, DR; Kusewitt, DF; Mulligan, LT, 1999
)
0.79

Dosage Studied

ExcerptRelevanceReference
" Dose-response modelling of the data for hepatocellular adenomas and carcinomas in female mice gave a BMDL10 of 20 mg/kg-bw/day."( Application of the margin of exposure (MOE) approach to substances in food that are genotoxic and carcinogenic. Example: leucomalachite green.
Leblanc, JC; Renwick, A; Setzer, RW, 2010
)
0.57
" To overcome these biases, we developed the PROgressive SAmple Dosage (PROSAD) platform and tested it."( PROSAD: a powerful platform for instrument calibration and quantification.
Cristoni, S; Floridia, M, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzenoid aromatic compound
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (27)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency48.96623.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency27.30600.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency4.70800.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency51.84680.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743063
progesterone receptorHomo sapiens (human)Potency13.68540.000417.946075.1148AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency3.98010.000214.376460.0339AID588532; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency24.49790.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency23.79000.000817.505159.3239AID1159527; AID1159531; AID588544; AID588546
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency31.89030.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency44.66840.375827.485161.6524AID588526
pregnane X nuclear receptorHomo sapiens (human)Potency33.17910.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.54940.000229.305416,493.5996AID743075
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency14.12540.001019.414170.9645AID588536
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency50.11870.023723.228263.5986AID588541
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency27.535719.739145.978464.9432AID1159509
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency39.81070.010039.53711,122.0200AID588545
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency23.43750.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency27.30600.000627.21521,122.0200AID651741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HTH-type transcriptional regulator qacRStaphylococcus aureusKd1.43000.72001.19331.7700AID977611
Chain B, HTH-type transcriptional regulator qacRStaphylococcus aureusKd1.43000.72001.19331.7700AID977611
Chain A, HTH-type transcriptional regulator qacRStaphylococcus aureusKd1.43000.72001.19331.7700AID977611
Chain B, HTH-type transcriptional regulator qacRStaphylococcus aureusKd1.43000.72001.19331.7700AID977611
Chain A, HTH-type transcriptional regulator qacRStaphylococcus aureusKd1.43000.72001.19331.7700AID977611
Chain A, HTH-type transcriptional regulator qacRStaphylococcus aureusKd1.43000.72001.19331.7700AID977611
Chain B, HTH-type transcriptional regulator qacRStaphylococcus aureusKd1.43000.72001.19331.7700AID977611
Chain A, HTH-type transcriptional regulator qacRStaphylococcus aureusKd1.43000.72001.19331.7700AID977611
Chain B, HTH-type transcriptional regulator qacRStaphylococcus aureusKd1.43000.72001.19331.7700AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2008Biochemistry, Aug-05, Volume: 47, Issue:31
QacR-cation recognition is mediated by a redundancy of residues capable of charge neutralization.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (87)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.15)18.7374
1990's9 (10.34)18.2507
2000's30 (34.48)29.6817
2010's42 (48.28)24.3611
2020's5 (5.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.62 (24.57)
Research Supply Index4.58 (2.92)
Research Growth Index5.57 (4.65)
Search Engine Demand Index64.51 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.04%)5.53%
Reviews3 (3.13%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other92 (95.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]